ArticlePloS one2026
Testosterone reduces uterine contractions in vivo: Evidence for non-genomic action in rats.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Non-Genomic Actions of Testosterone Metabolites on Uterine Contractility in Rats.Pharmaceutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the non-genomic effect of testosterone (T) on uterine muscle contractility in non-pregnant and 22nd day pregnant rats, in vivo. It provides the first evidence of an in vivo T uterine relaxation effect during pregnancy. Circulating T levels were measured within 8 hours after a single intraperitoneal (ip) administration of T (10 mg/kg) by ELISA. The kinetic curves of a single dose of T (10 mg/kg of ip) were estimated for 8 hours; plasma T was measured using ELISA kits. The rapid in vivo action of T was studied by measuring contractions using strain-gauge sensors in 15-minute intervals, and the AUC was calculated. The animals received T alone (3/10/30/100/300 mg/kg ip), with flutamide (100 mg/kg ip), solvent (DMSO+Macrogol 25% + 75%, 1 ml/kg ip) or normal saline (1 ml/kg) (n = 5-8/group, 160-220 g). To verify the possible mechanism of action, we also examined the uterine relaxing effect of T (10-4 M) and nifedipine (10-7 M) in vitro on KCl (40 mM)-stimulated contractions by cumulatively increasing the concentration of CaCl2 (1-120 mM) in the organ bath. Plasma T and 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) levels were measured by ELISA before and 30-minutes after administration (n = 4-8/group, 200-220 g). T had similar half-life and tmax values in both non-pregnant and pregnant rats, however, the AUC values were higher in pregnant animals. T (30/100/300 mg/kg single ip dose) elicited a flutamide-resistant dose-dependent uterine relaxing effect in both non-pregnant and 22nd day pregnant rats. T plasma levels were proportional with the administered doses. 4-HPPD plasma levels remained unchanged in both non-pregnant and 22nd day pregnant rats after 30 min of T administration. A single dose T induces rapid, non-genomic, dose-dependent uterine relaxation via blocking of calcium effect in non-pregnant and late-pregnant rats in vivo. Based on our results, T or its analogues might be good candidates for further pre-clinical and clinical studies for uterine hyperactivity-related conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.